Repligen Announces Publication of the Company’s 2022 Sustainability Report
14 Noviembre 2023 - 6:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced the digital
publication of its 2022 Sustainability Report and related reporting
index disclosures. Themed “Making an Impact”, the report highlights
the company’s measurable progress across multiple environmental,
social and governance (ESG) initiatives since its inaugural 2020
Sustainability Report, “Committed to Making a Difference”.
Supporting the 2022 Sustainability Report is a Reporting Indexes
document containing disclosures against the following frameworks:
Global Reporting Initiative (GRI) Standards, Sustainability
Accounting Standards Board (SASB), United Nations Sustainable
Development Goals (UN SDGs), and Task Force on Climate-Related
Disclosures (TCFD).
Tony Hunt, Chief Executive Officer at Repligen said, “Our
initial Sustainability report published in 2021 elevated awareness
in the company and prompted higher levels of action across the ESG
spectrum. We saw strong ratings and rankings as a result and are
pleased to share this next 2022 progress report, while continuing
to work toward positively impacting some of our more challenging
initiatives and collaboration-based goals.”
Dianne Heiler, Senior Director of Packaging and Head of
Sustainability at Repligen said, “I’m proud to be part of the team
at Repligen that is driving progress across multiple sustainability
ambitions, with the full support and participation of our executive
team and Board. As this report publishes, already we are expanding
the scope of our efforts and will submit a commitment letter by
year end 2023 to SBTi* to lower total GHG emissions in alignment
with the latest climate science.”
Below are just a few of the 2022 Sustainability Report
highlights. Report data is through year end 2022 unless otherwise
noted.
Environmental impacts:
- Reduced greenhouse gas (GHG) emissions intensity by 40% since
year end 2020.
- Transitioned to 100% renewable energy at 9 of 18 sites
representing 75% of our global consumption.
- Added Scope 3 emissions tracking and benchmarking for 9 of 15
GHG Protocol categories.
Social impacts:
- Advanced workplace diversity:
- New hires: In 2022, 41% of Manager level (Associate Director
and above) new hires were Women (global), and 37% were People of
Color (U.S.).
- Overall: At year end 2022, 27% of Managers were Women, compared
to 22% in 2020, and 26% of Managers were People of Color, compared
to 20% in 2020.
Governance impacts:
- Fortified our cybersecurity systems and protocols, implemented
a Zero Trust framework.
- Updated our charters and policies to maintain strong governance
practices, including shareholder proxy access.
Survey participation:
- In 2023, we completed our first CDP Climate survey and CDP
Water survey, each for the year 2022.
- In 2022, a pilot study of 12% our Tier 1 suppliers completed
sustainability surveys by our request, to help build our Scope 3
emissions inventory. In addition, we completed over one dozen
sustainability surveys by request of our customers.
*SBTi: Science Based Targets initiative
About Repligen
CorporationRepligen Corporation is a global life sciences
company that develops and commercializes highly innovative
bioprocessing technologies and systems that enable efficiencies in
the process of manufacturing biological drugs. We are “inspiring
advances in bioprocessing” for the customers we serve; primarily
biopharmaceutical drug developers and contract development and
manufacturing organizations (CDMOs) worldwide. Our focus areas are
Filtration and Fluid Management, Chromatography, Process Analytics
and Proteins. Our corporate headquarters are located in Waltham,
Massachusetts, and the majority of our manufacturing sites are in
the U.S., with additional key sites in Estonia, France, Germany,
Ireland, the Netherlands and Sweden. For more information, please
visit www.repligen.com, and follow us on LinkedIn.
Forward Looking Statements
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Repligen Contact: Sondra S. NewmanGlobal Head
of Investor Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Repligen (NASDAQ:RGEN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024